
MC2 Therapeutics has sold off the exclusive rights to selling the firm's new cream treating plaque psoriasis in Europe.
The cream, Wynzora, is currently being assessed by the European Medicines Agency, but was approved by the US Food and Drug Administration last year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app